Additionally, we discuss the clinical aspects by exploring how CXCL1 levels relate to cancer staging, lymph node metastasis, patient outcomes, chemoresistance, and radioresistance. This evidence concerns the gene CXCL1 and metastatic malignant neoplasm in the lymph nodes.